Moleculin Biotech Files 8-K with Corporate Updates
Ticker: MBRX · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1659617
Sentiment: neutral
Topics: corporate-filing, 8-K
Related Tickers: MBRX
TL;DR
Moleculin Biotech (MBRX) filed an 8-K on 9/8/25 detailing corporate info & exhibits.
AI Summary
Moleculin Biotech, Inc. filed an 8-K on September 8, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at 5300 Memorial Drive, Suite 950, Houston, TX 77007, and its telephone number is (713) 300-5160. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing provides essential corporate information and disclosures for investors and stakeholders, including the company's address and contact details.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- Moleculin Biotech, Inc. (company) — Registrant
- September 8, 2025 (date) — Date of Report
- 5300 Memorial Drive, Suite 950, Houston, TX 77007 (address) — Principal executive offices
- 713-300-5160 (phone_number) — Registrant's telephone number
- Delaware (jurisdiction) — State of Incorporation
- December 31 (date) — Fiscal Year End
FAQ
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is MOLECULIN BIOTECH, INC.
On what date was this Form 8-K filed?
The Form 8-K was filed on September 8, 2025.
What is the company's principal executive office address?
The company's principal executive offices are located at 5300 Memorial Drive, Suite 950, Houston, TX 77007.
What is the registrant's telephone number?
The registrant's telephone number is (713) 300-5160.
In which state was Moleculin Biotech, Inc. incorporated?
Moleculin Biotech, Inc. was incorporated in Delaware.
Filing Stats: 574 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-09-08 08:30:16
Filing Documents
- mbrx20250905_8k.htm (8-K) — 26KB
- ex_859503.htm (EX-99.1) — 15KB
- m01.jpg (GRAPHIC) — 12KB
- 0001437749-25-028528.txt ( ) — 207KB
- mbrx-20250908.xsd (EX-101.SCH) — 3KB
- mbrx-20250908_def.xml (EX-101.DEF) — 11KB
- mbrx-20250908_lab.xml (EX-101.LAB) — 15KB
- mbrx-20250908_pre.xml (EX-101.PRE) — 11KB
- mbrx20250905_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure On September 8, 2025, Moleculin Biotech, Inc. (the "Company"), issued a press release which announced that it has enrolled the first two subjects, and treated one, in the European Union (EU) in its pivotal Phase 2B/3, multi-center, randomized, double-blind, placebo-controlled, adaptive design study of Annamycin in combination with cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is referred to as "AnnAraC") for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy (R/R AML). A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated September 8, 2025 104 Cover page Interactive Data File (formatted as Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MOLECULIN BIOTECH, INC. Date: September 8, 2025 By: /s/ Jonathan P. Foster Jonathan P. Foster